JP2021521138A - Ｂｃｌ−２阻害剤 - Google Patents

Ｂｃｌ−２阻害剤 Download PDF

Info

Publication number
JP2021521138A
JP2021521138A JP2020555218A JP2020555218A JP2021521138A JP 2021521138 A JP2021521138 A JP 2021521138A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2021521138 A JP2021521138 A JP 2021521138A
Authority
JP
Japan
Prior art keywords
ring
heterocyclyl
alkyl
compound according
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020555218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521138A5 (https=
JPWO2019210828A5 (https=
Inventor
グオ、ユンハン
シュエ、ハイ
ワン、ジウェイ
ソン、ハンジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2021521138A publication Critical patent/JP2021521138A/ja
Publication of JP2021521138A5 publication Critical patent/JP2021521138A5/ja
Publication of JPWO2019210828A5 publication Critical patent/JPWO2019210828A5/ja
Priority to JP2024094048A priority Critical patent/JP7540113B1/ja
Priority to JP2024135320A priority patent/JP7688210B2/ja
Priority to JP2025085498A priority patent/JP2025119001A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020555218A 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤 Withdrawn JP2021521138A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024094048A JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018085217 2018-04-29
CNPCT/CN2018/085217 2018-04-29
CN2018107134 2018-09-21
CNPCT/CN2018/107134 2018-09-21
PCT/CN2019/085001 WO2019210828A1 (en) 2018-04-29 2019-04-29 Bcl-2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094048A Division JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤

Publications (3)

Publication Number Publication Date
JP2021521138A true JP2021521138A (ja) 2021-08-26
JP2021521138A5 JP2021521138A5 (https=) 2022-04-22
JPWO2019210828A5 JPWO2019210828A5 (https=) 2022-04-22

Family

ID=68386968

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555218A Withdrawn JP2021521138A (ja) 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Country Status (22)

Country Link
US (3) US11420968B2 (https=)
EP (2) EP3788042B1 (https=)
JP (4) JP2021521138A (https=)
KR (1) KR102738032B1 (https=)
CN (3) CN117683029A (https=)
AU (1) AU2019264475C1 (https=)
BR (1) BR112020022092A2 (https=)
CA (1) CA3098348A1 (https=)
DK (1) DK3788042T3 (https=)
ES (1) ES3018793T3 (https=)
FI (1) FI3788042T3 (https=)
HR (1) HRP20250392T1 (https=)
HU (1) HUE071493T2 (https=)
IL (1) IL278366B2 (https=)
LT (1) LT3788042T (https=)
MX (2) MX2020011495A (https=)
PL (1) PL3788042T3 (https=)
PT (1) PT3788042T (https=)
SG (1) SG11202009933WA (https=)
SI (1) SI3788042T1 (https=)
TW (1) TWI855062B (https=)
WO (1) WO2019210828A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119916A (ja) * 2018-04-29 2024-09-03 ベイジーン リミテッド Ｂｃｌ－２阻害剤
JP2024540534A (ja) * 2021-12-06 2024-10-31 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HUE060310T2 (hu) 2017-04-18 2023-02-28 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-indukáló szerek
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
KR20220100992A (ko) 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
JP7839962B2 (ja) * 2020-04-15 2026-04-03 ビーワン メディシンズ ワン ゲーエムベーハー Ｂｃｌ－２阻害剤
EP4146649A4 (en) * 2020-05-08 2024-09-11 Fochon Biosciences, Ltd. COMPOUNDS AS BCL-2 INHIBITORS
CN114478520B (zh) * 2020-10-28 2025-01-10 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN117642157A (zh) * 2021-03-19 2024-03-01 伊尔治疗学股份有限公司 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
EP4351542A4 (en) * 2021-06-02 2025-04-09 BeiGene Switzerland GmbH Method for treating B-cell malignancy with BCL-2 inhibitor
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
CA3230314A1 (en) * 2021-08-31 2023-03-09 Beigene Switzerland Gmbh Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
US20250122191A1 (en) * 2021-11-20 2025-04-17 Fochon Biosciences, Ltd Compounds as bcl-2 inhibitors
TW202400163A (zh) 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
CN119365456A (zh) * 2022-06-01 2025-01-24 重庆复创医药研究有限公司 作为bcl-2抑制剂的化合物
CN119584963A (zh) * 2022-07-21 2025-03-07 百济神州(苏州)生物科技有限公司 使用bcl-2抑制剂治疗多发性骨髓瘤的方法
WO2024140690A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. Intermediates of sonrotoclax and the method of preparing the same
AU2023416871A1 (en) * 2022-12-27 2025-08-14 Beone Medicines I Gmbh Salts and solid forms of sonrotoclax intermediate
WO2024140678A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. A ketal protected intermediate for sonrotoclax and preparation method thereof
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof
WO2026019442A1 (en) * 2024-07-14 2026-01-22 Eil Therapeutics, Inc. Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528178A (ja) * 2009-05-26 2012-11-12 アボット・ラボラトリーズ 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013527202A (ja) * 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
CN106749233A (zh) * 2016-11-24 2017-05-31 中山大学 一类磺酰胺衍生物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2577752A1 (en) 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
WO2006127364A1 (en) 2005-05-24 2006-11-30 Abbott Laboratories Apoptosis promoters
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
CN102112445B (zh) 2008-06-09 2014-06-18 百时美施贵宝公司 作为抗细胞凋亡Bcl抑制剂的羟基苯基磺酰胺
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
AU2009326259A1 (en) 2008-12-08 2011-07-28 Boehringer Ingelheim International Gmbh Compounds for treating cancer
CN102282129A (zh) 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282128B (zh) 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
WO2011029842A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
SG192126A1 (en) 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
CN104039797B (zh) 2011-10-12 2016-06-01 南京奥昭生物科技有限公司 作为细胞凋亡诱导剂的杂环分子
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
MX2014007732A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
BR112014015442A8 (pt) 2011-12-23 2017-07-04 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
KR102318204B1 (ko) 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
WO2018041248A1 (zh) 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HUE060310T2 (hu) 2017-04-18 2023-02-28 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-indukáló szerek
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528178A (ja) * 2009-05-26 2012-11-12 アボット・ラボラトリーズ 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013527202A (ja) * 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
CN106749233A (zh) * 2016-11-24 2017-05-31 中山大学 一类磺酰胺衍生物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUG AND METABOLISM AND DISPOSITION, vol. 45(3), JPN6023040641, 2017, pages 294 - 305, ISSN: 0005165092 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119916A (ja) * 2018-04-29 2024-09-03 ベイジーン リミテッド Ｂｃｌ－２阻害剤
JP2024540534A (ja) * 2021-12-06 2024-10-31 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用
JP7765790B2 (ja) 2021-12-06 2025-11-07 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用

Also Published As

Publication number Publication date
CA3098348A1 (en) 2019-11-07
HRP20250392T1 (hr) 2025-05-23
CN112437772A (zh) 2021-03-02
FI3788042T3 (fi) 2025-04-07
HUE071493T2 (hu) 2025-09-28
IL278366B2 (en) 2025-09-01
US20220402915A1 (en) 2022-12-22
TW202043217A (zh) 2020-12-01
MX2020011495A (es) 2021-01-15
CN112437772B (zh) 2023-11-21
TWI855062B (zh) 2024-09-11
SG11202009933WA (en) 2020-11-27
AU2019264475B2 (en) 2024-09-26
CN117430601A (zh) 2024-01-23
EP3788042B1 (en) 2025-02-12
DK3788042T3 (en) 2025-04-07
EP3788042A4 (en) 2022-01-26
PT3788042T (pt) 2025-04-15
JP2025119001A (ja) 2025-08-13
EP4545515A1 (en) 2025-04-30
PL3788042T3 (pl) 2025-06-02
US11420968B2 (en) 2022-08-23
AU2019264475C1 (en) 2025-01-30
WO2019210828A1 (en) 2019-11-07
BR112020022092A2 (pt) 2021-02-02
IL278366A (https=) 2020-12-31
ES3018793T3 (en) 2025-05-19
IL278366B1 (en) 2025-05-01
SI3788042T1 (sl) 2025-06-30
MX2023001689A (es) 2023-02-22
JP7540113B1 (ja) 2024-08-26
EP3788042A1 (en) 2021-03-10
JP2024119916A (ja) 2024-09-03
KR20210005677A (ko) 2021-01-14
CN117683029A (zh) 2024-03-12
JP2024161475A (ja) 2024-11-19
US20240376104A1 (en) 2024-11-14
AU2019264475A1 (en) 2020-11-12
US12077536B2 (en) 2024-09-03
LT3788042T (lt) 2025-03-25
KR102738032B1 (ko) 2024-12-05
JP7688210B2 (ja) 2025-06-03
US20210269433A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7688210B2 (ja) Ｂｃｌ－２阻害剤
AU2017279014B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
JP2022517222A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN113905787A (zh) Mettl3抑制化合物
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
CN114929689A (zh) Bcl-2抑制剂
JP7839790B2 (ja) Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体
CN105732636A (zh) 杂芳化合物及其在药物中的应用
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN114302886A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
EA043978B1 (ru) ИНГИБИТОРЫ Bcl-2
HK40038513A (en) Bcl-2 inhibitors
HK40038513B (en) Bcl-2 inhibitors
HK40078656A (en) Bcl-2 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
OA19125A (en) Substituted carbonucleoside derivatives useful as anticancer agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240710